Showing 4031-4040 of 8584 results for "".
- L'Oréal's SkinCeuticals USA Appoints Angela Hildebrand as General Managerhttps://practicaldermatology.com/news/loreals-skinceuticals-usa-appoints-angela-hildebrand-as-general-manager/2461975/Angela Hildebrand is SkinCeuticals’ new General Manager and Amy Sloan is the Senior Vice President of Business Strategy and Growth. "With their collective knowledge, expertise, and dedication to excellence, Angela and Amy's leadership are poised to tak
- Study Links Gut Microbiome and Eczema in Infancyhttps://practicaldermatology.com/news/study-links-gut-microbiome-and-eczema-in-infancy/2461971/New research has revealed associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota. The study was
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</
- New Kerecis Medical-Fish-Skin Product Approved by Medicare Administrative Contractorshttps://practicaldermatology.com/news/new-kerecis-medical-fish-skin-product-approved-by-medicare-administrative-contractors/2461961/Multiple leading Medicare Administrative Contractors have approved Kerecis Shield, the new fish-skin wound-treatment product. This means that physicians in private clinics will not need to submit invoices for reimbursement, improving efficiency by eliminating a step in the reimbursement proc
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove
- New App-controlled Device May Help Quickly Identify Infected Woundshttps://practicaldermatology.com/news/new-app-controlled-device-may-help-quickly-identify-infected-wounds/2461959/A new app-controlled device may allow doctors to spot infected wounds faster. The scientists developed a device called the Swift Ray 1 which can be attached to a smartphone and connected to the Swift Skin and Wound software. It can take medical-grade photographs, inf
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi